Stefan Dan Cezar M.
- Country
- Romania
- Department
- Cardiologie I
Research Overview
- Long-term Safety and Efficacy Evaluation of Ralinepag in Pulmonary Arterial Hypertension: An Open-label Extension Study
- Evaluation of Ralinepag Efficacy and Safety in Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Phase 3 Multicenter Study on Lorundrostat Efficacy and Safety in Uncontrolled and Resistant Hypertension
Data & Insights
Has run more than one trial at 432 of 871 partner sites.
Specializations
Coronary and Atherosclerotic Cardiovascular Disease
Clinical research activity includes acute coronary syndrome, acute myocardial infarction, established cardiovascular disease, and primary prevention of atherosclerotic cardiovascular disease, with attention to reducing recurrent ischemic events and broader cardiovascular risk.
- Major adverse cardiovascular events
- Recurrent myocardial infarction
- High cardiovascular risk
- Stroke prevention
The therapeutic focus also extends to lipid-lowering strategies and treatments aimed at lowering the burden of vascular complications in patients with high baseline risk.
Heart Failure and Cardiomyopathy
Research involvement covers chronic heart failure, heart failure with reduced ejection fraction, symptomatic heart failure, and transthyretin amyloidosis with cardiomyopathy, reflecting a strong interest in advanced cardiac disease.
- Heart failure with reduced ejection fraction
- Heart failure with preserved or mildly reduced ejection fraction
- Cardiomyopathy-related heart failure
- Hospitalization for heart failure
Therapeutic domains include agents directed at improving heart failure outcomes, addressing congestion and decompensation, and supporting care in structural and infiltrative cardiac disease.
Pulmonary Arterial Hypertension
The investigator is actively involved in pulmonary arterial hypertension research, including disease-modifying and symptom-directed approaches for patients with advanced pulmonary vascular disease.
- Exercise capacity
- Long-term safety and tolerability
- Clinical worsening in PAH
- Background PAH therapy
This area reflects a therapeutic interest in pulmonary vasodilator strategies and sustained management of severe cardiopulmonary impairment.
Atrial Fibrillation and Thromboembolic Prevention
Clinical trial participation includes atrial fibrillation with emphasis on preventing stroke and systemic embolism, alongside evaluation of antithrombotic strategies that balance efficacy and bleeding risk.
- Cardioembolic event prevention
- Ischemic stroke prevention
- Major bleeding risk
- Anticoagulation alternatives
The therapeutic landscape also includes acute antiplatelet intervention in suspected myocardial infarction, linking rhythm-related thrombosis prevention with broader vascular protection.
Hypertension, Lipids, and Metabolic Cardiovascular Risk
Research activity spans hypertension, uncontrolled and resistant hypertension, and severe hypertriglyceridemia, with additional attention to patients whose risk is amplified by cardiovascular comorbidity.
- Blood pressure control
- Resistant hypertension
- Triglyceride lowering
- Cardiometabolic risk reduction
These interests are complemented by work in therapies targeting renal-vascular pathways and metabolic contributors to cardiovascular disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.